Loading…
Reported covered position: Deputy Press Secretary, Senator Orrin Hatch
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
COALITION FOR ENERGY ASSISTANCE MODERNIZATION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to funding and administration of the Low Income Home Energy Assistance Program (LIHEAP).
Issues related to funding and administration of the Low Income Home Energy Assistance Program (LIHEAP).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| NORTHPORT HEALTH SERVICES |
| 39 |
| 2017–2026 |
| OPTIONS CLEARING CORPORATION (OCC) | 39 | 2016–2025 |
| NOVARTIS, INC. | 35 | 2019–2026 |
| WALGREENS CO. | 34 | 2018–2026 |
| NATIONAL ASSOCIATION OF PROTON THERAPY | 29 | 2019–2026 |
| ALEXION PHARMACEUTICALS, INC. | 28 | 2020–2026 |
| LILLY USA, LLC | 28 | 2020–2026 |
| GILEAD SCIENCES, INC. | 27 | 2020–2026 |
| HCR MANORCARE | 27 | 2016–2022 |
| VIR BIOTECHNOLOGY, INC. | 26 | 2020–2026 |
| TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION | 22 | 2021–2026 |
| EMERGENT BIOSOLUTIONS | 20 | 2019–2023 |
| SIEMENS CORPORATION | 20 | 2016–2021 |
| BIO-RAD LABORATORIES | 19 | 2021–2025 |
| LUMEN TECHNOLOGIES SERVICE GROUP, LLC | 19 | 2017–2022 |
| ULTRAGENYX PHARMACEUTICAL | 19 | 2019–2023 |
| ANTIMICROBIAL INNOVATION ALLIANCE | 18 | 2021–2025 |
| LUNDBECK LLC | 18 | 2017–2021 |
| Sorrento Therapeutics, Inc. | 18 | 2017–2021 |
| ABBOTT LABORATORIES | 17 | 2016–2020 |
| BAYER CORPORATION | 17 | 2019–2022 |
| HORIZON THERAPEUTICS | 17 | 2020–2023 |
| SAREPTA THERAPEUTICS | 17 | 2018–2022 |
| GLOBAL MEDICAL RESPONSE | 16 | 2022–2026 |
| GENOVAC, LLC | 14 | 2020–2023 |
| VERDE TECHNOLOGIES | 14 | 2019–2022 |
| A PLACE FOR MOM, INC. | 12 | 2019–2022 |
| DELOITTE LLP | 12 | 2018–2021 |
| LYKOS THERAPEUTICS | 12 | 2023–2024 |
| CAPITOL SOLUTIONS ON BEHALF OF BIPARTISAN POLICY CENTER ADVOCACY NETWORK, INC. | 11 | 2019–2022 |
| ADAPT PHARMA INC. | 10 | 2016–2018 |
| MILANAPHARM | 10 | 2019–2021 |
| VIRPAX PHARMACEUTICALS | 10 | 2019–2021 |
| HALOZYME THERAPEUTICS, INC. | 9 | 2019–2021 |
| REVANGENIX | 9 | 2024–2025 |
| BIPARTISAN POLICY CENTER ACTION | 8 | 2022–2023 |
| HEALTHY.IO (US), INC. | 8 | 2023–2025 |
| CONTESSA HEALTH, INC. | 7 | 2020–2021 |
| EVOLUS BEAUTY | 7 | 2019–2020 |
| HOMEWARD HEALTH | 7 | 2023–2024 |
| MOLINA HEALTHCARE, INC. | 7 | 2020–2021 |
| VENATORX PHARMACEUTICALS | 7 | 2021–2022 |
| CYTOVALE INC | 6 | 2024–2025 |
| UNIVERSITY OF SOUTHERN CALIFORNIA | 6 | 2020–2021 |
| AEON BIOPHARMA | 5 | 2019–2020 |
| EYEPOINT PHARMACEUTICALS, INC. | 5 | 2020–2021 |
| SANOFI U.S. | 5 | 2019 |
| T-MOBILE | 5 | 2016–2017 |
| WE ARE GOLF | 5 | 2017–2018 |
| ARCTURUS THERAPEUTICS | 4 | 2020–2021 |
| TARSUS PHARMACEUTICALS | 4 | 2025–2026 |
| VIEMED HEALTHCARE, INC. | 4 | 2020–2021 |
| BELLEROPHON THERAPEUTICS | 3 | 2020 |
| CONDUENT BUSINESS SERVICES, LLC | 3 | 2023–2024 |
| PRIMMUNE THERAPEUTICS | 3 | 2020–2021 |
| SPERO THERAPEUTICS, INC. | 3 | 2021–2022 |
| ABYRX, INC. | 2 | 2020 |
| ARGENTUM | 2 | 2023 |
| BOMBARDIER RECREATIONAL PRODUCTS | 2 | 2017–2018 |
| COALITION FOR ENERGY ASSISTANCE MODERNIZATION | 2 | 2026 |
| EUSA PHARMA LLC | 2 | 2020 |
| EVOLVA INC. | 2 | 2018 |
| I AM ALS | 2 | 2026 |
| STORER TEST EXPRESS DBA BUSTEST EXPRESS | 2 | 2021 |
| SYNDAX PHARMACEUTICALS | 2 | 2020 |
| UROVANT SCIENCES | 2 | 2020 |
| KAHALA BIOSCIENCES | 1 | 2020 |
| NATIONAL MARINE MANUFACTURERS ASSOCIATION | 1 | 2018 |
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act; Issues related to the forthcoming CY 2027 Physician Fee Schedule Proposed Rule regarding possible establishment of a national reimbursement structure for proton beam therapy treatment.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act; Issues related to the CY 2026 Physician Fee Schedule Final Rule regarding reimbursement for proton beam therapy treatment.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act; Issues related to the forthcoming CY 2027 Physician Fee Schedule Proposed Rule regarding possible establishment of a national reimbursement structure for proton beam therapy treatment.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
Ensuring Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Ensuring Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Ensuring Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.
Ensuring Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.
Ensuring Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44); Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Doctor Knows Best Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Doctor Knows Best Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44); Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Doctor Knows Best Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44); Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act; Issues related to the CY 2026 Physician Fee Schedule Final Rule regarding reimbursement for proton beam therapy treatment.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act; Issues related to the forthcoming CY 2027 Physician Fee Schedule Proposed Rule regarding possible establishment of a national reimbursement structure for proton beam therapy treatment.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act; Issues related to the forthcoming CY 2027 Physician Fee Schedule Proposed Rule regarding possible establishment of a national reimbursement structure for proton beam therapy treatment.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44); Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Radiology Outpatient Ordering Transmission (ROOT) Act
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44); Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Radiology Outpatient Ordering Transmission (ROOT) Act
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Radiology Outpatient Ordering Transmission (ROOT) Act
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Equitable Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.
Equitable Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to S.3822 - Break Up Big Medicine Act.
Issues related to S.3822 - Break Up Big Medicine Act.
Issues related to S.3822 - Break Up Big Medicine Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Bipartisan Health Care Act
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
2026 · third_quarter · Q3
Issues related to corporate tax, net operating loss, and EBITA/EBIDA.
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Pharmacy Benefit Managers.
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to vaccines; Issues related to the FDA certification process; Issues related to Pharmacy Benefit Managers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
I AM ALS via FORBES-TATE
2026 · third_quarter · Q3
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHRMA via FORBES-TATE
2026 · third_quarter · Q3
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
NOVARTIS, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
ELI LILLY AND COMPANY FKA LILLY USA, LLC via FORBES-TATE
2026 · third_quarter · Q3
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (PL 119-21).
GENENTECH via FORBES-TATE
2026 · third_quarter · Q3
Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
AMGEN USA, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Issues related to surprise billing; Issues related to prior authorization in Medicare and Medicaid.
ALEXION PHARMACEUTICALS, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to orphan drugs under the Drug Price Negotiation Program.
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NORTHPORT HEALTH SERVICES via FORBES-TATE
2026 · third_quarter · Q3
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post-acute care reform.
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, post-acute care reform, the Older Americans Act (PL 89-73), intergenerational therapy; Issues related to Medicare requirements for participation.
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post-acute care reform.
NATIONAL ASSOCIATION OF PROTON THERAPY via FORBES-TATE
2026 · third_quarter · Q3
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act; Issues related to the forthcoming CY 2027 Physician Fee Schedule Proposed Rule regarding possible establishment of a national reimbursement structure for proton beam therapy treatment.
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2026 · third_quarter · Q3
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to S.3822 - Break Up Big Medicine Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation Program in the One Big Beautiful Bill Act (PL 119-21).
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2026 · third_quarter · Q3
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260); Issues related to Medicaid plan amendments.
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Issues related to FEMA emergency transport response.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
AMGEN USA, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Issues related to surprise billing; Issues related to prior authorization in Medicare and Medicaid.
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2026 · second_quarter · Q2
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation Program in the One Big Beautiful Bill Act (P.L. 119-21).
Issues related to S.3822 - Break Up Big Medicine Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
ALEXION PHARMACEUTICALS, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to orphan drugs under the Drug Price Negotiation Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
STRATHSPEY CROWN HOLDINGS, LLC via FORBES-TATE
2026 · second_quarter · Q2
Issues related to CMS coverage decisions and issues related to healthcare reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · second_quarter · Q2
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Pharmacy Benefit Managers.
Issues related to corporate tax, net operating loss, EBITA/EBIDA.
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to vaccines; Issues related to the FDA certification process; Issues related to Pharmacy Benefit Managers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2026 · second_quarter · Q2
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260); Issues related to Medicaid plan amendments.
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Issues related to FEMA emergency transport response.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
NORTHPORT HEALTH SERVICES via FORBES-TATE
2026 · second_quarter · Q2
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, post-acute care reform, the Older Americans Act (PL 89-73), intergenerational therapy; Issues related to Medicare requirements for participation.
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post-acute care reform.
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post-acute care reform.
NATIONAL ASSOCIATION OF PROTON THERAPY via FORBES-TATE
2026 · second_quarter · Q2
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act; Issues related to the forthcoming CY 2027 Physician Fee Schedule Proposed Rule regarding possible establishment of a national reimbursement structure for proton beam therapy treatment.
Issues pertaining to veterans' access to proton therapy.
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.
PHRMA via FORBES-TATE
2026 · second_quarter · Q2
Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to pharmacy benefit managers.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
NOVARTIS, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
ELI LILLY AND COMPANY FKA LILLY USA, LLC via FORBES-TATE
2026 · second_quarter · Q2
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
GENENTECH via FORBES-TATE
2026 · second_quarter · Q2
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues related to the 340B Drug Pricing Program.
Intellectual property and process patent related issues.
COALITION FOR ENERGY ASSISTANCE MODERNIZATION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to funding and administration of the Low Income Home Energy Assistance Program (LIHEAP).
Issues related to funding and administration of the Low Income Home Energy Assistance Program (LIHEAP).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
I AM ALS via FORBES-TATE
2026 · third_quarter · RR
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2026 · first_quarter · Q1
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
2026 · first_quarter · Q1
Issues related to corporate tax, net operating loss, EBITA/EBIDA.
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to vaccines; Issues related to the FDA certification process; Issues related to Pharmacy Benefit Managers.
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Pharmacy Benefit Managers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2026 · first_quarter · Q1
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TARSUS PHARMACEUTICALS via FORBES-TATE
2026 · first_quarter · Q1
Issues related to education and advocacy pertaining to life science products and pipeline.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRATHSPEY CROWN HOLDINGS, LLC via FORBES-TATE
2026 · first_quarter · Q1
Issues related to CMS coverage decisions and issues related to healthcare reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NORTHPORT HEALTH SERVICES via FORBES-TATE
2026 · first_quarter · Q1
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post-acute care reform.
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, post-acute care reform, the Older Americans Act (PL 89-73), intergenerational therapy; Issues related to Medicare requirements for participation.
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post-acute care reform.
NATIONAL ASSOCIATION OF PROTON THERAPY via FORBES-TATE
2026 · first_quarter · Q1
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act; Issues related to the CY 2026 Physician Fee Schedule Final Rule regarding reimbursement for proton beam therapy treatment.
Issues pertaining to veterans' access to proton therapy.
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2026 · first_quarter · Q1
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260); Issues related to Medicaid plan amendments.
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Issues related to FEMA emergency transport response.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PHRMA via FORBES-TATE
2026 · first_quarter · Q1
Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
NOVARTIS, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
GENENTECH via FORBES-TATE
2026 · first_quarter · Q1
Issues related to the 340B Drug Pricing Program.
Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
ELI LILLY AND COMPANY FKA LILLY USA, LLC via FORBES-TATE
2026 · first_quarter · Q1
Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
ALEXION PHARMACEUTICALS, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to orphan drugs under the Drug Price Negotiation Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN USA, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION via FORBES-TATE
2026 · first_quarter · Q1
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Issues related to surprise billing; Issues related to prior authorization in Medicare and Medicaid.
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44); Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
2025 · fourth_quarter · Q4
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to vaccines; Issues related to the FDA certification process; Issues related to Pharmacy Benefit Managers.
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Pharmacy Benefit Managers.
Issues related to corporate tax, net operating loss, EBITA/EBIDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANTIMICROBIAL INNOVATION ALLIANCE via FORBES-TATE
2025 · fourth_quarter · 4T
Issues related to the development of critical need antimicrobial biopharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2477 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2477 - Equitable Community Access to Pharmacist Services Act.
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260); Issues related to Medicaid plan amendments.
Issues related to FEMA emergency transport response.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2025 · fourth_quarter · Q4
Issues related to biopharmaceutical research and innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NORTHPORT HEALTH SERVICES via FORBES-TATE
2025 · fourth_quarter · Q4
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post-acute care reform.
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, post-acute care reform, the Older Americans Act (PL 89-73), intergenerational therapy; Issues related to Medicare requirements for participation.
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post-acute care reform.
NATIONAL ASSOCIATION OF PROTON THERAPY via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act; Issues related to the CY 2026 Physician Fee Schedule Final Rule regarding reimbursement for proton beam therapy treatment.
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.
Issues related to continued access to and provider reimbursement for proton beam therapy; Issues related to the Fiscal Year 2026 Labor-HHS appropriations process.
AMGEN USA, INC. via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
PHRMA via FORBES-TATE
2025 · fourth_quarter · Q4
Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to pharmacy benefit managers.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
NOVARTIS, INC. via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
ELI LILLY AND COMPANY FKA LILLY USA, LLC via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025.
AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act.
ALEXION PHARMACEUTICALS, INC. via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to orphan drugs under the Drug Price Negotiation Program.
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TARSUS PHARMACEUTICALS via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to education and advocacy pertaining to life science products and pipeline.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRATHSPEY CROWN HOLDINGS, LLC via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to CMS coverage decisions and issues related to healthcare reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via FORBES-TATE
2025 · fourth_quarter · Q4
Intellectual property and process patent related issues.
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
AMGEN USA, INC. via FORBES-TATE
2025 · third_quarter · Q3
Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to Puerto Rico tax; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
ANTIMICROBIAL INNOVATION ALLIANCE via FORBES-TATE
2025 · third_quarter · Q3
Issues related to the development of critical need antimicrobial biopharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION via FORBES-TATE
2025 · third_quarter · Q3
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act.
ALEXION PHARMACEUTICALS, INC. via FORBES-TATE
2025 · third_quarter · Q3
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to low-volume Diagnosis Related Groups (DRG); Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to orphan drugs under the Drug Price Negotiation Program.
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIO-RAD LABORATORIES via FORBES-TATE
2025 · third_quarter · Q3
Issues related to biomedical research and development; Issues related to pathogen surveillance.
Issues related to biomedical research and development; Issues related to pathogen surveillance.
Issues related to advanced diagnostic testing and laboratory tools.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2025 · third_quarter · Q3
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Transportation issues regarding medical transport.
2025 · third_quarter · Q3
Issues related to biopharmaceutical research and innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OPTIONS CLEARING CORPORATION (OCC) via FORBES-TATE
2025 · third_quarter · Q3
Issues related to financial services and tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NORTHPORT HEALTH SERVICES via FORBES-TATE
2025 · third_quarter · Q3
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post-acute care reform.
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post-acute care reform.
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, post-acute care reform, the Older Americans Act (P.L. 89-73), intergenerational therapy; Issues related to Medicare requirements for participation.
NATIONAL ASSOCIATION OF PROTON THERAPY via FORBES-TATE
2025 · third_quarter · Q3
Issues pertaining to veterans' access to proton therapy.
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.
GILEAD SCIENCES, INC. via FORBES-TATE
2025 · third_quarter · Q3
Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2025 · third_quarter · Q3
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to vaccines; Issues related to the FDA certification process; Issues related to Pharmacy Benefit Managers.
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Pharmacy Benefit Managers.
Issues related to corporate tax, net operating loss, EBITA/EBIDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2025 · third_quarter · Q3
Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2025 · third_quarter · Q3
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TARSUS PHARMACEUTICALS via FORBES-TATE
2025 · third_quarter · Q3
Issues related to Education and advocacy pertaining to life science products and pipeline.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRATHSPEY CROWN HOLDINGS, LLC via FORBES-TATE
2025 · third_quarter · Q3
Issues related to CMS coverage decisions and issues related to healthcare reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via FORBES-TATE
2025 · third_quarter · Q3
Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to pharmacy benefit managers.
NOVARTIS, INC. via FORBES-TATE
2025 · third_quarter · Q3
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to World Trade Organization IP waiver; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2025 · third_quarter · Q3
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2477 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2477 - Equitable Community Access to Pharmacist Services Act.
ELI LILLY AND COMPANY FKA LILLY USA, LLC via FORBES-TATE
2025 · third_quarter · Q3
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - the Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025.
GENENTECH via FORBES-TATE
2025 · third_quarter · Q3
Intellectual property and process patent related issues.
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2025 · second_quarter · Q2
Issues related to Medicare reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Transportation issues regarding medical transport; Issues related to airport development and planning, facilities and equipment, and operations.
Issues related to Medicare reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GILEAD SCIENCES, INC. via FORBES-TATE
2025 · second_quarter · Q2
Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
HEALTHY.IO (US), INC. via FORBES-TATE
2025 · second_quarter · Q2
Issues related to kidney health and Medicare Advantage.
Issues related to kidney health and Medicare Advantage.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2025 · second_quarter · Q2
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation Program in H.R. 1 - the One Big Beautiful Bill Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act.
AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION via FORBES-TATE
2025 · second_quarter · Q2
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act.
Issues related to proposed cuts in the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to Medicare physician fee schedule.
Issues related to surprise billing; Issues related to prior authorization in Medicare and Medicaid.
BIO-RAD LABORATORIES via FORBES-TATE
2025 · second_quarter · Q2
Issues related to biomedical research and development; Issues related to pathogen surveillance.
Issues related to biomedical research and development; Issues related to pathogen surveillance.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · second_quarter · Q2
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to FDA certification process; Issues related to Pharmacy Benefit Managers.
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Pharmacy Benefit Managers.
Issues related to corporate tax, net operating loss, EBITA/EBIDA.
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2025 · second_quarter · Q2
Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ANTIMICROBIAL INNOVATION ALLIANCE via FORBES-TATE
2025 · second_quarter · Q2
Issues related to the development of critical need antimicrobial biopharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN USA, INC. via FORBES-TATE
2025 · second_quarter · Q2
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (PL 116-260); Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to Puerto Rico tax; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to pharmacy benefit managers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to intellectual property and process patent.
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues related to the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to continued access to and provider reimbursement for proton beam therapy; Issues related to the Fiscal Year 2027 Labor-HHS appropriations process.
Issues pertaining to veterans' access to proton therapy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to continued access to and provider reimbursement for proton beam therapy; Issues related to the Fiscal Year 2027 Labor-HHS appropriations process.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to S.3822 - Break Up Big Medicine Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation Program in the One Big Beautiful Bill Act (P.L. 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to continued access to and provider reimbursement for proton beam therapy; Issues related to the Fiscal Year 2027 Labor-HHS appropriations process.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to pharmacy benefit managers.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Intellectual property and process patent related issues.
Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2477 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation Program in the One Big Beautiful Bill Act (P.L. 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to veterans' access to proton therapy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to World Trade Organization IP waiver; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to proposed cuts in the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to Medicare physician fee schedule.
Issues related to surprise billing; Issues related to prior authorization in Medicare and Medicaid.
Issues related to the Medicare Physician Fee Schedule and Authorized Use Criteria (AUC) in the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (PL 116-260); Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to proposed cuts in the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to Medicare physician fee schedule.
Issues related to surprise billing; Issues related to prior authorization in Medicare and Medicaid.
Issues related to the Medicare Physician Fee Schedule and Authorized Use Criteria (AUC) in the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to FEMA emergency transport response.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to continued access to and provider reimbursement for proton beam therapy; Issues related to the Fiscal Year 2026 Labor-HHS appropriations process.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2477 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation Program in the One Big Beautiful Bill Act (P.L. 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the Medicare Physician Fee Schedule and Authorized Use Criteria (AUC) in H.R. 1 - One Big Beautiful Bill Act.
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE